SM
APLS

SG3 Management’s Apellis Pharmaceuticals APLS Stock Holding History

SG3 Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,000
Closed -$1.14M – 21
2022
Q4 		$1.14M Sell
22,000
-18,000
-45% -$955K 0.16% 77
2022
Q3 		$2.73M Buy
40,000
+38,845
+3,363% +$2.3M 0.37% 57
2022
Q2 		$52K Buy
+1,155
New +$52.7K 0.01% 350
2021
Q4 		– Sell
-100,000
Closed -$3.3M – 1026
2021
Q3 		$3.3M Buy
100,000
+90,000
+900% +$5.06M 0.1% 201
2021
Q2 		$632K Buy
+10,000
New +$516K 0.02% 601

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG3 Management's APLS Position: Q1 2023 in Review

SG3 Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 22,000 shares — an estimated $1.14M sold.

SG3 Management first reported a position in APLS in Q2 2021 and held it in 5 quarters. The position peaked at $3.3M in Q3 2021. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • SG3 Management reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 22,000 Apellis Pharmaceuticals shares in Q1 2023, an estimated $1.14M.
  • SG3 Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • SG3 Management's Apellis Pharmaceuticals position peaked at $3.3M in Q3 2021.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.